GENFIT (GNFT) Competitors $4.18 -0.07 (-1.53%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GNFT vs. AVBP, PHAT, CRMD, MRVI, VIR, DNA, AVXL, TNGX, ABUS, and PVLAShould you be buying GENFIT stock or one of its competitors? The main competitors of GENFIT include ArriVent BioPharma (AVBP), Phathom Pharmaceuticals (PHAT), CorMedix (CRMD), Maravai LifeSciences (MRVI), Vir Biotechnology (VIR), Ginkgo Bioworks (DNA), Anavex Life Sciences (AVXL), Tango Therapeutics (TNGX), Arbutus Biopharma (ABUS), and Palvella Therapeutics (PVLA). These companies are all part of the "pharmaceutical products" industry. GENFIT vs. Its Competitors ArriVent BioPharma Phathom Pharmaceuticals CorMedix Maravai LifeSciences Vir Biotechnology Ginkgo Bioworks Anavex Life Sciences Tango Therapeutics Arbutus Biopharma Palvella Therapeutics ArriVent BioPharma (NASDAQ:AVBP) and GENFIT (NASDAQ:GNFT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk. Which has stronger valuation & earnings, AVBP or GNFT? GENFIT has higher revenue and earnings than ArriVent BioPharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArriVent BioPharmaN/AN/A-$80.49M-$4.02-4.88GENFIT$41.52M5.01$1.63MN/AN/A Does the media refer more to AVBP or GNFT? In the previous week, ArriVent BioPharma and ArriVent BioPharma both had 2 articles in the media. GENFIT's average media sentiment score of 0.83 beat ArriVent BioPharma's score of 0.39 indicating that GENFIT is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GENFIT 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer AVBP or GNFT? ArriVent BioPharma presently has a consensus target price of $39.14, indicating a potential upside of 99.40%. GENFIT has a consensus target price of $7.00, indicating a potential upside of 68.27%. Given ArriVent BioPharma's stronger consensus rating and higher probable upside, research analysts plainly believe ArriVent BioPharma is more favorable than GENFIT.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ArriVent BioPharma 2 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.67GENFIT 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders & institutionals have more ownership in AVBP or GNFT? 9.5% of ArriVent BioPharma shares are held by institutional investors. Comparatively, 2.2% of GENFIT shares are held by institutional investors. 18.6% of ArriVent BioPharma shares are held by insiders. Comparatively, 4.2% of GENFIT shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is AVBP or GNFT more profitable? GENFIT's return on equity of 0.00% beat ArriVent BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets ArriVent BioPharmaN/A -55.40% -51.97% GENFIT N/A N/A N/A Which has more volatility & risk, AVBP or GNFT? ArriVent BioPharma has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, GENFIT has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. SummaryArriVent BioPharma and GENFIT tied by winning 6 of the 12 factors compared between the two stocks. Get GENFIT News Delivered to You Automatically Sign up to receive the latest news and ratings for GNFT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNFT vs. The Competition Export to ExcelMetricGENFITMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$208.01M$3.38B$6.13B$10.46BDividend YieldN/A2.30%5.73%4.78%P/E RatioN/A23.0785.1527.20Price / Sales5.01446.16574.61178.68Price / Cash59.6246.1137.3961.86Price / Book2.7710.5012.396.65Net Income$1.63M-$52.47M$3.32B$276.79M7 Day Performance-2.80%-1.00%-0.24%-1.51%1 Month Performance-0.72%14.49%9.56%5.46%1 Year Performance-33.76%13.92%71.67%36.25% GENFIT Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNFTGENFIT2.0559 of 5 stars$4.16-1.9%$7.00+68.3%-29.1%$208.01M$41.52M0.00120Positive NewsAnalyst ForecastGap UpAVBPArriVent BioPharma1.504 of 5 stars$20.90+0.2%$39.14+87.3%-27.6%$846.27MN/A-5.2040Analyst DowngradePHATPhathom Pharmaceuticals2.8114 of 5 stars$12.53+6.0%$17.50+39.7%-14.1%$838.55M$55.25M-2.65110CRMDCorMedix3.3007 of 5 stars$10.58-1.4%$18.00+70.1%+5.2%$837.57M$43.47M14.1130MRVIMaravai LifeSciences3.6511 of 5 stars$3.30+3.4%$5.22+58.1%-59.3%$814.60M$259.18M-2.43610News CoverageAnalyst ForecastOptions VolumeVIRVir Biotechnology3.5128 of 5 stars$5.86+1.0%$17.30+195.2%-21.7%$805.72M$74.21M-1.47580News CoverageAnalyst ForecastInsider TradeDNAGinkgo Bioworks1.1803 of 5 stars$13.20-2.4%$9.00-31.8%+102.5%$800.38M$230.82M-2.25640Gap UpAVXLAnavex Life Sciences3.7132 of 5 stars$8.62-7.0%$44.00+410.4%+67.5%$796.24MN/A-15.1240TNGXTango Therapeutics1.4321 of 5 stars$8.47+18.6%$10.50+24.0%+37.8%$794.40M$42.07M-6.3790ABUSArbutus Biopharma1.28 of 5 stars$4.28+4.1%$5.00+16.8%+8.8%$787.88M$6.17M-14.7690PVLAPalvella Therapeutics1.8669 of 5 stars$76.22+9.0%$75.50-0.9%N/A$773.07M$42.81M-6.30N/AShort Interest ↑ Related Companies and Tools Related Companies ArriVent BioPharma Alternatives Phathom Pharmaceuticals Alternatives CorMedix Alternatives Maravai LifeSciences Alternatives Vir Biotechnology Alternatives Ginkgo Bioworks Alternatives Anavex Life Sciences Alternatives Tango Therapeutics Alternatives Arbutus Biopharma Alternatives Palvella Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNFT) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredIs *BSEM* Oversold??BioStem Technologies Inc. (OTC: BSEM) is emerging as one of the most exciting MedTech stories of 2025. The com...Huge Alerts | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GENFIT S.A. Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share GENFIT With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
